NCT05806047尚未招募2 期
Phase II Clinical Study of Combination of Chidamide and Fulvestrant for HR+/HER2- Breast Cancer That Has Failed Prior Adjuvant Therapy With CDK4/6 Inhibitors
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 23
- 主要终点
- ORR
研究概览
简要总结
This trial is a single-arm study. The purpose of the trial is to evaluate the efficacy and safety of chidamide and fulvestrant in HR+/HER2- breast cancer that has failed prior adjuvant endocrine therapy with CDK4/6 inhibitors.
详细描述
The study was a single-center, single-arm, open trial design. Twenty-three patients with advanced HR+/HER2- breast cancer who had failed previous adjuvant treatment with CDK4/6 inhibitors in combination with endocrine therapy were treated with fulvestrant and chidamide.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Female, ≥18 years old;
- •ECOG score 0-1;
- •Predicted survival ≥3 months;
- •Patients with locally advanced and/or metastatic breast cancer confirmed by histopathology with positive ER expression and negative ER2 expression;
- •Patients who have relapsed or metastasized during or after CDK4/6 inhibitors combined with endocrine adjuvant therapy and have not received systemic antitumor therapy for the current stage of disease;
- •No previous treatment with fluvestran or use of fluvestran without proven treatment failure;
- •The time interval between non-endocrine therapy should be ≥2 weeks;
- •At least one extracranial measurable lesion as defined by RECIST V1.1 criteria;
- •The functions of vital organs meet the requirements;
- •Fertile subjects must have a negative pregnancy test 7 days before starting treatment and must use an appropriate contraceptive method during treatment and for three months after completion of treatment;
- •The patient is fully informed and voluntarily signs the informed consent.
排除标准
- •Prior treatment with any HDAC inhibitors;
- •Known allergy to the tested drug component;
- •inflammatory breast cancer at the time of screening;
- •pia meningeal metastasis confirmed by MRI or lumbar puncture;
- •Central nervous system metastasis confirmed by imaging;
- •To the best of the investigator's judgment, symptomatic visceral disease or any disease load or none is considered optimal Endocrine therapy options are not suitable for endocrine therapy;
- •Inability or unwillingness to swallow medication or receive intramuscular injections;
- •Gastrointestinal insufficiency or gastrointestinal disease (if not controlled) that may significantly affect study drug absorption Ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small intestine resection, etc.;
- •Patients with ascites, pleural effusion and pericardial effusion accompanied by clinical symptoms in the baseline period need drainage, or use it for the first time Patients with serous cavity drainage within 4 weeks before medication;
- •A history of immunodeficiency, including HIV positive, or other acquired or congenital immunodeficiency conditions, Or have a history of organ transplantation;
- •Other malignancies (cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, and Thyroid cancer is excluded);
- •had undergone major surgical procedures or significant trauma within 4 weeks prior to the start of treatment, or was expected to undergo major surgery Surgical treatment;
- •Concomitant diseases that, in the investigator's judgment, seriously endanger patient safety or interfere with patient completion of the study (e.g.
- •Severe hypertension, diabetes, thyroid disease, co-active hepatitis B/C, and other activities Sexual infection);
- •Inability to understand or follow research instructions and requirements;
- •The researcher decides that it is not suitable to participate in this study
研究组 & 干预措施
chidamide combined with fulvestrant
Experimental
chidamide combined with fulvestrant
干预措施: chidamide combined with fulvestrant (Drug)
结局指标
主要结局
ORR
时间窗: max 6 months
The proportion of participants whose best outcome is complete remission or partial remission (according to RECIST1.1)
次要结局
- CBR(max 6 months)
- PFS(Randomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the end of study (approximately 1 years))
- DOR(max 6 months)
研究者
相似试验
Unknown
2 期
Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHLRelapsed or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)NCT03245905Sun Yat-sen University100
Unknown
2 期
Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell LymphomaDiffuse Large B-cell LymphomaNCT02733380Henan Cancer Hospital20
Unknown
2 期
A Phase II Trail of Chidamide ,Rituximab and Methotrexate in Lymphoma PatientsCentral Nervous System LymphomaNCT04516655Fudan University51
Unknown
2 期
Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell LymphomaPeripheral T Cell LymphomaNCT02753543Ruijin Hospital33
Unknown
2 期
Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 BlockadeEsophageal Squamous Cell CarcinomaNCT04984018The First Affiliated Hospital of Zhengzhou University73